These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 25677230)

  • 1. The role of intermittent androgen deprivation therapy in the management of biochemically recurrent or metastatic prostate cancer.
    Jaswal J; Crook J
    Curr Urol Rep; 2015 Mar; 16(3):11. PubMed ID: 25677230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials.
    Sciarra A; Abrahamsson PA; Brausi M; Galsky M; Mottet N; Sartor O; Tammela TL; Calais da Silva F
    Eur Urol; 2013 Nov; 64(5):722-30. PubMed ID: 23628492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature.
    Abrahamsson PA
    Eur Urol; 2010 Jan; 57(1):49-59. PubMed ID: 19683858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy.
    Strum SB; Scholz MC; McDermed JE
    Oncologist; 2000; 5(1):45-52. PubMed ID: 10706649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Degarelix as an intermittent androgen deprivation therapy for one or more treatment cycles in patients with prostate cancer.
    Boccon-Gibod L; Albers P; Morote J; van Poppel H; de la Rosette J; Villers A; Malmberg A; Neijber A; Montorsi F
    Eur Urol; 2014 Oct; 66(4):655-63. PubMed ID: 24954791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy.
    Schulman C; Irani J; Aapro M
    BJU Int; 2012 Jun; 109 Suppl 6():13-21. PubMed ID: 22672121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer.
    Langenhuijsen JF; Badhauser D; Schaaf B; Kiemeney LA; Witjes JA; Mulders PF
    Urol Oncol; 2013 Jul; 31(5):549-56. PubMed ID: 21561791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate Study VII: quality of life and adverse effects.
    Salonen AJ; Taari K; Ala-Opas M; Viitanen J; Lundstedt S; Tammela TL;
    Eur Urol; 2013 Jan; 63(1):111-20. PubMed ID: 22857983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of continuous vs intermittent androgen deprivation therapy: redefining the gold standard in the treatment of advanced prostate cancer. Myths, facts and new data on a ″perpetual dispute″.
    Kratiras Z; Konstantinidis C; Skriapas K
    Int Braz J Urol; 2014; 40(1):3-15; discussion 15. PubMed ID: 24642162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis.
    Botrel TE; Clark O; dos Reis RB; Pompeo AC; Ferreira U; Sadi MV; Bretas FF
    BMC Urol; 2014 Jan; 14():9. PubMed ID: 24460605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial.
    Mottet N; Van Damme J; Loulidi S; Russel C; Leitenberger A; Wolff JM;
    BJU Int; 2012 Nov; 110(9):1262-9. PubMed ID: 22502816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of intermittent and continuous androgen deprivation and quality of life between patients with locally advanced and patients with metastatic prostate cancer: a post hoc analysis of the randomized FinnProstate Study VII.
    Salonen AJ; Taari K; Ala-Opas M; Sankila A; Viitanen J; Lundstedt S; Tammela TL;
    Scand J Urol; 2014 Dec; 48(6):513-22. PubMed ID: 24679247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revisiting Intermittent Therapy in Metastatic Prostate Cancer: Can Less Be More in the "New World Order"?
    Shevach J; Sydes MR; Hussain M
    Eur Urol Focus; 2019 Mar; 5(2):125-133. PubMed ID: 30803926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is intermittent androgen-deprivation therapy beneficial for patients with advanced prostate cancer?
    Wolff JM; Abrahamsson PA; Irani J; da Silva FC
    BJU Int; 2014 Oct; 114(4):476-83. PubMed ID: 24433259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen deprivation therapy: evidence-based management of side effects.
    Ahmadi H; Daneshmand S
    BJU Int; 2013 Apr; 111(4):543-8. PubMed ID: 23351025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy.
    Tunn UW; Canepa G; Kochanowsky A; Kienle E
    Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):296-302. PubMed ID: 22733160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermittent androgen deprivation therapy may prolong the duration of androgen dependence of well-differentiated prostate cancer.
    Kaneko Y; Maekawa S; Arakaki R; Okada Y; Terada N; Nishimura K
    Hinyokika Kiyo; 2006 Apr; 52(4):259-64. PubMed ID: 16686352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials.
    Niraula S; Le LW; Tannock IF
    J Clin Oncol; 2013 Jun; 31(16):2029-36. PubMed ID: 23630216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermittent complete androgen blockade in metastatic prostate cancer.
    Rambeaud JJ
    Eur Urol; 1999; 35 Suppl 1():32-6. PubMed ID: 10081701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of intermittent androgen suppression in biochemically recurrent or newly diagnosed metastatic prostate cancer.
    Crook J
    Curr Opin Support Palliat Care; 2013 Sep; 7(3):258-64. PubMed ID: 23912384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.